Omalizumab in Severe and Refractory Solar Urticaria

NCT02262130 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Solar Urticaria

Interventions

DRUG: Omalizumab

Sponsor

Centre Hospitalier Universitaire de Besancon

Collaborators

[object Object]